Summit Therapeutics SMMT Free cash flow margin
Discontinued — last reported Q3 '22
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Summit Therapeutics’s 10-Q, filed November 7, 2023, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's free cash flow margin?
- Summit Therapeutics (SMMT) reported free cash flow margin of -5,931.6% in Q3 2022.
- How has Summit Therapeutics's free cash flow margin changed year-over-year?
- Summit Therapeutics's free cash flow margin decreased by 44.4% year-over-year, from -4,108.7% to -5,931.6%.
- What does free cash flow margin mean?
- How much real, spendable cash each sales dollar generates after reinvestment.
- How do you interpret free cash flow margin?
- A high and rising FCF margin is the hallmark of a cash-generative business. Persistent gaps between net margin and FCF margin warrant a look at working capital or capital intensity.
- How does free cash flow margin compare across companies?
- Strong cross-company quality signal; capital-light compounders post structurally higher FCF margins than asset-heavy peers.